Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Front Oncol · 2022 · PMC8864144 · PMID 35223476

Europe PMC DOI

hedged sentence

0.1730

closest p · 3.5× alpha

0.1730

boldest claim

The sentences

a numerical trendP = 0.173not close (p > 0.1)

When ICIs were compared to chemotherapy, ICIs were found to enhance OS (HR = 0.74; 95% CI: 0.59–0.92, P = 0.006), but the improvement in PFS and ORR was only a numerical trend (PFS: HR = 0.83; 95% CI: 0.63–1.09, P = 0.173; ORR: RR = 0.92, 95% CI: 0.77–1.10, P = 0.372).

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.